Fishman Jay A Ltd. MI decreased its holdings in shares of Allergan plc (NYSE:AGN) by 72.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,990 shares of the company’s stock after selling 5,300 shares during the quarter. Fishman Jay A Ltd. MI’s holdings in Allergan were worth $335,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also bought and sold shares of AGN. Prestige Wealth Management Group LLC purchased a new position in shares of Allergan in the 2nd quarter valued at $25,000. Old North State Trust LLC grew its holdings in Allergan by 172.4% during the 3rd quarter. Old North State Trust LLC now owns 158 shares of the company’s stock valued at $27,000 after buying an additional 100 shares in the last quarter. Motco purchased a new position in Allergan during the 2nd quarter valued at approximately $29,000. HM Payson & Co. purchased a new position in Allergan during the 2nd quarter valued at approximately $29,000. Finally, Reilly Financial Advisors LLC grew its holdings in Allergan by 129.3% during the 3rd quarter. Reilly Financial Advisors LLC now owns 172 shares of the company’s stock valued at $29,000 after buying an additional 97 shares in the last quarter. Institutional investors and hedge funds own 80.70% of the company’s stock.
Several equities analysts have weighed in on AGN shares. Sanford C. Bernstein cut Allergan from an “outperform” rating to a “market perform” rating and set a $166.08 price target for the company. in a report on Tuesday, July 16th. ValuEngine cut shares of Allergan from a “hold” rating to a “sell” rating in a report on Wednesday, October 30th. Svb Leerink reiterated a “market perform” rating and issued a $188.00 price objective (down from $217.00) on shares of Allergan in a report on Thursday, July 18th. UBS Group increased their price objective on shares of Allergan from $172.00 to $189.00 and gave the company a “buy” rating in a report on Thursday, September 12th. Finally, Royal Bank of Canada reiterated a “hold” rating and issued a $178.00 price objective on shares of Allergan in a report on Thursday, August 8th. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and five have given a buy rating to the company’s stock. Allergan currently has a consensus rating of “Hold” and an average target price of $175.16.
AGN stock traded up $2.60 on Friday, hitting $181.28. 2,332,139 shares of the company’s stock traded hands, compared to its average volume of 3,255,166. Allergan plc has a 1-year low of $114.27 and a 1-year high of $181.45. The stock has a market cap of $58.54 billion, a price-to-earnings ratio of 10.86, a P/E/G ratio of 2.11 and a beta of 1.66. The stock has a fifty day moving average of $171.62 and a 200-day moving average of $155.71. The company has a current ratio of 1.67, a quick ratio of 0.91 and a debt-to-equity ratio of 0.39.
Allergan (NYSE:AGN) last released its earnings results on Tuesday, November 5th. The company reported $4.25 EPS for the quarter, meeting the consensus estimate of $4.25. Allergan had a negative net margin of 58.50% and a positive return on equity of 9.08%. The business had revenue of $4.03 billion during the quarter, compared to analyst estimates of $3.88 billion. During the same period in the prior year, the business earned $4.25 earnings per share. The business’s quarterly revenue was up 2.9% on a year-over-year basis. On average, equities research analysts anticipate that Allergan plc will post 16.7 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 13th. Stockholders of record on Wednesday, November 13th will be paid a dividend of $0.74 per share. The ex-dividend date is Tuesday, November 12th. This represents a $2.96 annualized dividend and a dividend yield of 1.63%. Allergan’s dividend payout ratio (DPR) is 17.74%.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Featured Article: What is a Tariff?
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.